Global Bioenergies Past Earnings Performance
Past criteria checks 0/6
Global Bioenergies has been growing earnings at an average annual rate of 8.5%, while the Chemicals industry saw earnings growing at 7.4% annually. Revenues have been growing at an average rate of 48.6% per year.
Key information
8.5%
Earnings growth rate
25.9%
EPS growth rate
Chemicals Industry Growth | 10.4% |
Revenue growth rate | 48.6% |
Return on equity | -159.3% |
Net Margin | -1,514.5% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Global Bioenergies SA's (EPA:ALGBE) Intrinsic Value Is Potentially 60% Above Its Share Price
Sep 18Does Global Bioenergies (EPA:ALGBE) Have A Healthy Balance Sheet?
Jun 21Is Global Bioenergies (EPA:ALGBE) Using Debt Sensibly?
Jun 28Global Bioenergies (EPA:ALGBE) Has Debt But No Earnings; Should You Worry?
Oct 11Does Global Bioenergies (EPA:ALGBE) Have A Healthy Balance Sheet?
Oct 25Global Bioenergies (EPA:ALGBE) Shareholders Have Enjoyed An Impressive 187% Share Price Gain
Mar 20Revenue & Expenses Breakdown
How Global Bioenergies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 0 | -7 | 10 | 0 |
31 Mar 24 | 2 | -8 | 10 | 0 |
31 Dec 23 | 3 | -9 | 11 | 0 |
30 Sep 23 | 4 | -9 | 10 | 0 |
30 Jun 23 | 4 | -10 | 13 | 0 |
31 Mar 23 | 2 | -11 | 14 | 0 |
31 Dec 22 | 1 | -12 | 14 | 0 |
30 Sep 22 | 1 | -11 | 13 | 0 |
30 Jun 22 | 1 | -10 | 13 | 0 |
31 Mar 22 | 1 | -11 | 13 | 0 |
31 Dec 21 | 1 | -12 | 14 | 0 |
30 Sep 21 | 0 | -12 | 16 | 0 |
30 Jun 21 | 0 | -12 | 14 | 0 |
31 Mar 21 | 0 | -11 | 14 | 0 |
31 Dec 20 | 0 | -11 | 13 | 0 |
30 Sep 20 | 0 | -13 | 13 | 0 |
30 Jun 20 | 0 | -12 | 13 | 0 |
31 Mar 20 | 0 | -12 | 13 | 0 |
31 Dec 19 | 0 | -14 | 13 | 0 |
30 Sep 19 | 1 | -13 | 10 | 0 |
30 Jun 19 | 1 | -12 | 13 | 0 |
31 Mar 19 | 1 | -13 | 13 | 0 |
31 Dec 18 | 1 | -14 | 14 | 0 |
30 Sep 18 | 1 | -16 | 15 | 0 |
30 Jun 18 | 0 | -17 | 16 | 0 |
31 Mar 18 | 0 | -16 | 15 | 0 |
31 Dec 17 | 0 | -14 | 14 | 0 |
30 Sep 17 | 0 | -11 | 13 | 0 |
30 Jun 17 | 1 | -10 | 13 | 0 |
31 Mar 17 | 1 | -10 | 13 | 0 |
31 Dec 16 | 1 | -11 | 14 | 0 |
30 Sep 16 | 0 | -11 | 16 | 0 |
30 Jun 16 | 1 | -11 | 12 | 0 |
31 Mar 16 | 1 | -11 | 12 | 0 |
31 Dec 15 | 1 | -10 | 12 | 0 |
30 Sep 15 | 1 | -9 | 11 | 0 |
30 Jun 15 | 1 | -8 | 10 | 0 |
31 Mar 15 | 2 | -7 | 10 | 0 |
31 Dec 14 | 2 | -6 | 9 | 0 |
30 Sep 14 | 2 | -6 | 9 | -1 |
30 Jun 14 | 2 | -6 | 8 | -1 |
31 Mar 14 | 1 | -6 | 7 | -1 |
31 Dec 13 | 1 | -5 | 7 | -1 |
Quality Earnings: ALGBE is currently unprofitable.
Growing Profit Margin: ALGBE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALGBE is unprofitable, but has reduced losses over the past 5 years at a rate of 8.5% per year.
Accelerating Growth: Unable to compare ALGBE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALGBE is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-8.2%).
Return on Equity
High ROE: ALGBE has a negative Return on Equity (-159.25%), as it is currently unprofitable.